

## **Product Specification Sheet**

PHA-665752 **Product Name:** 

**Catalog Number:** C7665

**Technical information:** 

 $C_{32}H_{34}CI_2N_4O_4S$ Chemical Formula:

> CAS #: 477575-56-7

Molecular Weight: 641.61

> Purity: > 98%

Appearance: Yellow solid

Solubility: Soluble in DMSO up to 100 mM

Chemical Name: (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-

carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one

Storage: Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months

under proper storage condition.

Handling: • To make 10 mM stock solution, add 0.156mL of DMSO for each mg of PHA-665752.

• For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum

sample recovery.

**Biological Activity:** 

PHA-665752 is an oxindole-based, ATP-competitive c-Met and Ron inhibitor with IC50 potencies of 9 nM, and 68 nM, respectively. [1] It is >50-fold selective compared to a broad panel of both tyrosine and serine-threonine kinases. In cellular studies, PHA-665752 inhibits HGF-stimulated and constitutive c-Met phosphorylation as well as downstream signal transduction mediators such as Gab-1, Akt, phospholipase C gamma, and focal adhesion kinase. Inhibition of c-Met phosphorylation is dose-dependent and correlates well with tumor growth inhibition.

PHA-665752 induced apoptosis and cell cycle arrest in BaF3.TPR-MET cells at an IC50 of 60 nM. [2] Additionally, PHA-665752 has been suggested to inhibit lung tumorigenesis in mutant K-Ras mice and may be a formidable treatment for NSCLC. [3]

Reference: 1. Christensen et al., A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003, 63, 7345-7355. Pubmed ID: 14612533

> 2. Ma et al., A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin. Cancer Res. 2005, 11, 2312-2139 Pubmed ID: 15788682

> 3. Yang et al., A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol. Cancer Ther. 2008, 7, 952-960. Pubmed ID: 18413809

To reorder: http://www.cellagentech.com/PHA-665752/

technical@cellagentech.com For Technical Support:

Chemicals are sold for research use only, not for clinical or diagnostic use.